In vivo molecular target assessment of matrix metalloproteinase inhibition

Nature Medicine

Volumn 7, Issue 6, 2001, Pages 743-748

  Bremer, C ^a   Tung, C H ^a   Weissleder, R ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CYTOSTATIC AGENT; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; PRINOMASTAT; TANOMASTAT;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCOMPATIBILITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FLUORESCENCE; HUMAN; HUMAN CELL; IN VIVO STUDY; INFRARED RADIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE; DIAGNOSTIC IMAGING; FIBROSARCOMA; FLUORESCENCE; FLUORESCENT DYES; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASES; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; ORGANIC CHEMICALS; PEPTIDES; PROTEASE INHIBITORS; SPECTROSCOPY, NEAR-INFRARED;

ANIMALIA; MUS MUSCULUS;

EID: 0034954524     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/89126     Document Type: Article

References (43)

1. In vivo paracrine interaction between urokinase and its receptor: Effect on tumor cell invasion
2. Changing views of the role of matrix metalloproteinases in metastasis
3. Molecular regulation, membrane association and secretion of tumor cathepsin B
4. Type IV collagenase (M(r) 72,000) expression in human prostate: Benign and malignant tissue
5. Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion
6. Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications
7. Increased incidence of matrix metalloproteinases in urine of cancer patients
8. Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model
9. Structure of human pro-matrix metalloproteinase-2: Activation mechanism revealed
10. Design and therapeutic application of matrix metalloprotease inhibitors
11. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials
12. Clinical studies with matrix metalloproteinase inhibitors
13. Matrix metalloproteinases: Biologic activity and clinical implications
14. Tumor targeting with a selective gelatinase inhibitor
15. Preclinical and clinical studies of MMP inhibitors in cancer
16. Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer
17. Phase I study of the matrix metalloproteinase inhibitor, BAY 129566
18. Experimental models to identify antimetastatic drugs: Are we there yet? A position paper
19. Addition of matrix metalloproteinase inhibition to conventional cytotoxic therapy reduces tumor implantation and prolongs survival in a murine model of human pancreatic cancer
20. Ala-Pro-cresyl violet, a synthetic fluorogenic substrate for the analysis of kinetic parameters of dipeptidyl peptidase IV (CD26) in individual living rat hepatocytes
21. Heterogeneous suppression of experimentally induced colon cancer metastasis in rat liver lobes by inhibition of extracellular cathepsin B
22. In vivo imaging of tumors with protease-activated near-infrared fluorescent probes
23. In vivo imaging of proteolytic enzyme activity using a novel molecular reporter
24. Antibody-mediated versus nontargeted delivery in a human small cell lung carcinoma model
25. Cleavage specificity of human skin type IV collagenase (gelatinase). Identification of cleavage sites in type I gelatin, with confirmation using synthetic peptides
26. Substrate specificity of the human matrix metalloproteinase stromelysin and the development of continuous fluorometric assays
27. Overview of matrix metalloproteinase expression in cultured human cells
28. A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases
29. Preclinical evaluation and Phase I clinical trial of a 99mTc-labeled synthetic polymer used in blood pool imaging
30. Near-infrared images using continuous, phase-modulated, and pulsed light with quantitation of blood and blood oxygenation
31. Near-infrared optical imaging of protease activity for tumor detection
32. Concurrent MRI and diffuse optical tomography of breast after indocyanine green enhancement
33. Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models
34. Correlation of antiangiogenic and antitumor efficacy of N-biphenyl sulfonyl-phenylalanine hydroxiamic acid (BPHA), an orally-active, selective matrix metalloproteinase inhibitor
35. Atherosclerosis - An inflammatory disease
36. Expression of matrix metalloproteinase-1, -2 and -3 in squamous cell carcinoma and actinic keratosis
37. Increase in interphotoreceptor matrix gelatinase A (MMP-2) associated with age-related macular degeneration
38. A continuous fluorescence-based assay of human cytomegalovirus protease using a peptide substrate
39. Matrix metalloproteinases, tissue inhibitors of metalloproteinases, and glycosaminoglycans in synovial fluid from patients with rheumatoid arthritis
40. Cytokines secreted by glial cells infected with HTLV-I modulate the expression of matrix metalloproteinases (MMPs) and their natural inhibitor (TIMPs): Possible involvement in neurodegenerative processes
41. Preparation of a cathepsin D sensitive near-infrared fluorescence probe for imaging
42. Stetler-Stevenson, W.G. Independent expression and cellular processing of Mr 72,000 type IV collagenase and interstitial collagenase in human tumorigenic cell lines
43. H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen